Novartis Consumer Health Canada Inc. issues voluntary recall of certain over-the-counter products due to bottle closure defect

Novartis Consumer Health Canada Inc. issues voluntary recall of certain 
over-the-counter products due to bottle closure defect 


    --  Voluntary recall of Triaminic(®) and Jack & Jill(®) brand
        pediatric syrups and adult Buckley's Complete(®) liquids and
        NeoCitran(®) syrups issued to consumers
    --  There were no adverse events related to this issue reported to
        Novartis Consumer Health Canada, and Triaminic(®) and Jack &
        Jill(®) pediatric syrups, and adult Buckley's Complete(®)
        liquids and NeoCitran(®) syrups continue to be safe and
        effective when used as directed on the package label
    --  The products being recalled were produced at the Novartis
        Consumer Health Lincoln, Nebraska facility prior to the
        voluntarily suspension of operations in December 2011, and at a
        third-party manufacturing site using the same bottle and cap
        components.

MISSISSAUGA, ON, Jan. 31, 2013 /CNW/ - Novartis Consumer Health Canada Inc. 
announced today that it is voluntarily recalling Triaminic(®) and Jack & 
Jill(®) pediatric syrups, NeoCitran(®) syrups and certain Buckley's 
Complete(®) liquids. Novartis Consumer Health Canada Inc. has decided to 
issue a voluntary recall to consumers, retail customers and wholesalers 
because the child-resistant feature of the bottle cap may not function 
properly, enabling the cap to be removed when the tamper-evident seal is still 
in place.

The products being recalled were produced at the Novartis Consumer Health 
manufacturing facility in Lincoln, Nebraska prior to the voluntarily 
suspension of operations in December 2011. In addition to production at the 
Lincoln site, Buckley's Complete(®) was also manufactured until January 2013 
at a third-party site using the same Lincoln bottle and cap components. A 
consumer complaint in the US in late November 2012 triggered an internal 
investigation by Novartis Consumer Health that determined a voluntary recall 
was in the best interest of consumers.

Novartis Consumer Health Canada, Inc. has not received any adverse events due 
to the tamper evident seal causing a failure of the child resistant cap. 
Novartis Consumer Health in the United States received four adverse events for 
Triaminic(®) Syrups related to this issue.

All Triaminic(®), Jack & Jill(®), Buckley's Complete(®) and NeoCitran(®) 
products continue to be safe and effective when used as directed on the 
package label.

Novartis Consumer Health Canada Inc. advises consumers who think they might 
have the product(s) being recalled to visit our website at 
www.novartisOTCcanada.com or contact the Novartis Consumer Relationship Center 
at 1-866-513-6742 (Monday-Saturday 8 am - midnight Eastern Time) for more 
detailed information, including how to return the affected products.

Adverse events that may be related to the failure of child-resistant packaging 
of these products may be reported to the Novartis Consumer Relationship Center 
at 1-866-513-6742 (Monday-Saturday 8 am - midnight Eastern Time) or the Health 
Canada's Adverse Event Reporting Program by:
    --  Report online at
        www.healthcanada.gc.ca/medeffect
    --  Call toll-free at 1-866-234-2345


--  Complete a Canada Vigilance Reporting Form and:
  o Fax toll-free to 1-866-678-6789, or
  o Mail to: Canada Vigilance Program, Health Canada, Postal Locator 
0701D, Ottawa, K1A 0K9 
This recall is being conducted with the knowledge of Health Canada. 
Disclaimer
The foregoing release contains forward-looking statements including express or 
implied discussions regarding potential future revenues from Novartis OTC 
products. You should not place undue reliance on these statements. Such 
forward-looking statements reflect the current views of management regarding 
future events, and involve known and unknown risks, uncertainties and other 
factors that may cause actual results to be materially different from any 
future results, performance or achievements expressed or implied by such 
statements. There can be no guarantee that Novartis OTC products will achieve 
any particular levels of revenue in the future. In particular, management's 
expectations regarding such products could be affected by, among other things, 
unexpected regulatory actions or delays or government regulation generally; 
competition in general; government, industry and general public pricing 
pressures; unexpected manufacturing issues; the impact that the foregoing 
factors could have on the values attributed to the Novartis Group's assets and 
liabilities as recorded in the Group's consolidated balance sheet, and other 
risks and factors referred to in Novartis AG's current Form 20-F on file with 
the US Securities and Exchange Commission. Should one or more of these risks 
or uncertainties materialize, or should underlying assumptions prove 
incorrect, actual results may vary materially from those anticipated, 
believed, estimated or expected. Novartis is providing the information in this 
press release as of this date and does not undertake any obligation to update 
any forward-looking statements contained in this press release as a result of 
new information, future events or otherwise. 
About Novartis
Novartis provides innovative healthcare solutions that address the evolving 
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis 
offers a diversified portfolio to best meet these needs: innovative medicines, 
eye care, cost-saving generic pharmaceuticals, preventive vaccines and 
diagnostic tools, over-the-counter and animal health products. Novartis is the 
only global company with leading positions in these areas. In 2012, the Group 
achieved net sales of USD 56.7 billion, while R&D throughout the Group 
amounted to approximately USD 9.3 billion (USD 9.1 billion excluding 
impairment and amortization charges). Novartis Group companies employ 
approximately 128,000 full-time-equivalent associates and operate in more than 
140 countries around the world. For more information, please visit 
http://www.novartis.com. 
Novartis is on Twitter. Sign up to follow @Novartis at 
http://twitter.com/novartis. 
Novartis Media Relations 
Julie Masow Novartis Corporation +1 212 830 2465 (direct) +1 862 579 8456 
(mobile) julie.masow@novartis.com 
Pamela McKinlay Novartis Consumer Health, Inc. +1 973 503 7337(direct) +1 862 
221 0151(mobile) pamela.mckinlay@novartis.com 
Milicent Brooks Novartis Consumer Health, Inc. +1 973 503 7483(direct) +1 973 
479 2078 (mobile) milicent.brooks@novartis.com  
Andrea Gilpin Novartis Pharma Canada inc. +1 514 631 6775 (x3356) (direct) +1 
514 465 2114 (cellulaire) andrea.gilpin@novartis.com 
e-mail:us.mediarelations@novartis.com 
For Novartis multimedia content, please visitwww.thenewsmarket.com/Novartis. 
For questions about the site or required registration, please 
contact:journalisthelp@thenewsmarket.com. 
SOURCE: Novartis Pharmaceuticals Canada Inc. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/January2013/31/c2231.html 
CO: Novartis Pharmaceuticals Canada Inc.
ST: Ontario
NI: MTC HEA MED HEA  
-0- Jan/31/2013 21:15 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.